Prothena Corp PLC (NAS:PRTA)
$ 21.04 -0.09 (-0.43%) Market Cap: 1.13 Bil Enterprise Value: 602.18 Mil PE Ratio: 0 PB Ratio: 2.25 GF Score: 64/100

Prothena Corporation PLC - PRX004 Phase 1 Study Results Transcript

Dec 09, 2020 / 01:30PM GMT
Release Date Price: $11.47 (-0.78%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Prothena conference call about PRX004 Phase I study results. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions) I would now hand the conference over to your speaker today, Ms. Ellen Rose, Head of Communication. Please go ahead, ma'am.

Ellen Rose
Prothena Corporation plc - Head of Communications

Thank you, and hello, everyone, and welcome to Prothena's investor conference call to review the positive results from the Phase I study of PRX004 in patients with ATTR amyloidosis. Please review the press release we issued earlier today, which is available on our website at prothena.com.

On today's call, Dr. Gene Kinney, our President and Chief Executive Officer, will provide introductory remarks. Dr. Wagner Zago, our Chief Scientific Officer, will then speak about ATTR amyloidosis, its underlying pathophysiology and key elements of PRX004's preclinical research.

Today, we will also be joined by 2 physicians with expertise in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot